最大雄激素阻断治疗前列腺癌患者的骨折风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入17项研究共16162例前列腺癌患者,比较最大雄激素阻断(MAB)与单用雄激素剥夺治疗(ADT)的骨折风险。结果显示各类型ARPI联合ADT均显著增加骨折风险(汇总OR 1.5–2.4),不同ARPI间风险无差异,作者建议普遍使用骨保护剂。
要点
- MAB较单用ADT显著增加骨折风险,汇总OR为1.5–2.4。
- 不同雄激素受体通路抑制剂(ARPI)之间的骨折风险无差异。
- 仅7项研究报告了骨保护剂(BPA)使用情况,建议普遍推荐BPA。
核心结论
- MAB较单用ADT显著增加骨折风险,且与ARPI类型无关。
- 鉴于长期MAB为多种前列腺癌场景的标准治疗,应普遍推荐使用骨保护剂。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed/Medline和Cochrane图书馆数据库。
- 纳入17项研究共16162例前列腺癌患者,其中MAB组9240例,单用ADT组6922例。
- 采用随机效应模型计算各类型ARPI的骨折汇总OR。
主要发现
- 各类型ADT+ARPI较单用ADT均显著增加骨折风险,汇总OR范围为1.5至2.4。
- 不同ARPI之间的骨折风险程度无差异。
- 仅7项研究报告了接受骨保护剂治疗的患者数量。
关键数值与推荐
- 汇总OR范围为1.5至2.4,对应各类型ARPI联合ADT对比单用ADT的骨折风险。
临床怎么用
- 对接受MAB的前列腺癌患者应普遍推荐使用骨保护剂。
- 骨保护剂的剂量和频率需根据具体前列腺癌治疗场景调整。
局限性
- 仅7项研究报告了骨保护剂使用情况,相关数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Addition of an androgen receptor pathway inhibitor (ARPI) to androgen deprivation therapy (ADT) (ADT + ARPI, i.e., maximal androgen blockade, MAB) improves survival outcomes compared to ADT monotherapy in patients with prostate cancer (PC). It is known that ADT increases the risk of fractures in patients with PC, but it is unclear if this risk is higher with MAB. The aim of this study is to conduct a systematic review and meta-analysis to determine if MAB increases the incidence of fractures compared to ADT alone, and if the incidence of fractures was influenced by the type of ARPI. METHODS: Clinical trials assessing MAB versus ADT alone in patients with PC were identified using the PubMed/Medline and Cochrane library databases. The pooled odds ratio of developing fractures with MAB versus ADT alone was calculated for each type of ARPI in selected studies by random-effects modeling. The number of patients receiving bone-protecting agent (BPA) was also evaluated. RESULTS: We identified 17 studies comprising 16162 patients for the systematic review and meta-analysis (9240 patients treated with MAB, 6922 patients treated with ADT alone). Each type of ADT + ARPI resulted in a statistically significant increased risk of fractures compared to ADT alone (pooled OR ranging from 1.5 to 2.4). There was no difference in the magnitude of the risk of fractures among the different ARPIs. Only 7 studies reported the number of patients treated with a BPA. CONCLUSIONS: In our meta-analysis, MAB resulted in a statistically significant increase in fracture risk compared to ADT alone, regardless of the type of ARPI. Since long-term MAB represents the standard of care in various settings of PC, the use of a BPA should be generally recommended. Dosing and frequency of BPA need to be adapted according to the specific PC setting.
引用
- Saporita I, Calabrese M, Carfi FM, et al. Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis. Prostate Cancer Prostatic Dis. 2026. PMID: 41582208. doi:10.1038/s41391-026-01077-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。